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Supratentorial tumorsAbstract Background: Acute hypertension is a common accompaniment during emergence from
anesthesia especially in intracranial neurosurgical procedures and may be associated with the devel-
opment of intracranial hematoma. Although various drugs have been evaluated, management of
emergence hypertension in this subset of patients continues to be a challenge for anesthesiologists.
Methodology: Seventy-five patients ASA (I-II) scheduled for supratentorial craniotomy under gen-
eral anesthesia were randomly allocated to one of three groups at the time of dural closure: Group
‘‘dex” received dexmedetomidine infusion in a rate of 1 lg/kg/hr, Group ‘‘labetalol” received labe-
talol infusion in a rate of 0.5 mg/kg/hr, and Group ‘‘control” a control group where patients
received saline infusion at the same rate of dexmedetomidine and labetalol. Hypertensive episodes
were managed with nitroglycerin at a dose starting from 1 lg/kg/min if systolic blood pressure
exceeded 25% of its preinduction value. Hemodynamic parameters as well as the number of
patients, the total dose of nitroglycerin required in each group and the time to extubation were
recorded.
Results: Dexmedetomidine and labetalol had a significant effect in reducing SBP, MAP, DBP, HR
during emergence from anesthesia, with more reduction of the SBP, MAP and DBP in the
dexmedetomidine group and of the HR in the labetalol group in comparison with the other two
groups. The number of patients needing nitroglycerin was 8 representing 32% of patients in
dexmedetomidine group, 5 representing 20% of patients in labetalol group and 22 representing
88% of patients in control group (P value = 0.032). Time to emergence from anesthesia was com-
parable in the three groups.
Conclusion: Both dexmedetomidine and labetalol had favorable effects on hemodynamics at time
of emergence from anesthesia in comparison with control group without prolongation of the time of
extubation.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Perioperative hemodynamic stability is of utmost importance
in neurosurgical patients. An abrupt elevation of arterial blood
pressure (BP) during emergence from anesthesia has been asso-
ciated with many complications such as, postoperative
intracranial hemorrhage (ICH) though no direct causal rela-
tion has been identified, increased intracranial pressure, and
a prolonged hospital stay [1].
The incidence of perioperative hypertension has been
reported in various studies to be as wide as 54–91% [2–4]. In
a study by Basali et al. it was reported to be 57% for postcran-
iotomy hypertension [1].
Activation of the sympathetic nervous system appears to be
a fundamental component of emergence hypertension, as evi-
denced by elevated plasma catecholamine concentrations in
these patients [5], and other factors have been suggested
including pain, hypothermia and hypoxia [6,7]. Anesthesiolo-
gists have 2 options; either suppress this response if it occurred,
or prevent its occurrence at the outset. Suppression of this
response after release of endogenous catecholamines can be
treated with anti-hypertensive drugs which are not devoid of
side effects such as, an abrupt increase in intracranial pressure
and a decrease in intracranial compliance, hypotension, sinus
tachycardia, nausea, vomiting, sinus bradycardia, conduction
delays, left ventricular dysfunction, bronchospasm, nausea
and vomiting [8,9].
Anesthesiologists have long been using opioids, anesthetics,
and antihypertensive drugs to blunt hypertensive responses in
cranial surgeries at several critical moments such as intubation,
pinning, incision, closure, and extubation [10].
Labetalol a combined selective a1-adrenergic receptor
blocker and nonselective b-adrenergic blocker given by IV
bolus or continuous infusion, has been evaluated for the treat-
ment of acute postoperative hypertension following cardiac,
vascular, intracranial, and general surgeries. It has been found
to be a safe and effective option, producing overall response
rates of 85–100%. (8) However, its use in asthmatics, patients
with heart failure and severe sinus bradycardia should be
avoided. Moreover, its prolonged duration of action may mask
the hemodynamic response of a possible postoperative increase
in intracranial pressure that may manifest as hypertension and
bradycardia [2,7,8].
Dexmedetomidine a highly selective a2-adrenoceptor ago-
nist with sedative, anxiolytic, analgesic and hypotensive prop-
erties, has also been evaluated by several authors as an
adjuvant to anesthesia for neurosurgery with favorable periop-
erative hemodynamic control [11–15].
Although various drugs have been evaluated, management
of emergence hypertension in patients undergoing cranial surg-
eries continues to be a challenge. In the present study we com-
pare the effect of continuous IV infusion of dexmedetomidine
and labetalol on controlling emergence hypertension in cranial
surgeries for supratentorial tumors.
2. Materials & methods
2.1. Patient selection
After getting approval from the ethical committee of the anes-
thesia department at Cairo University and obtaining writteninformed consents from all patients, seventy-five patients
ASA (I-II) scheduled for supratentorial craniotomy under gen-
eral anesthesia were randomly allocated to one of three groups
using computer software (research randomizer.org). Numbers
were concealed by closed envelope.
In Group ‘‘dex” patients receive dexmedetomidine infusion
at time of dural closure, in Group ‘‘labetalol” patients receive
labetalol infusion at time of dural closure, and in Group ‘‘con-
trol” patients receive saline infusion at time of dural closure.
Exclusion criteria were as follows: age <18 or >65 years,
ASA physical status >II, patients with impaired renal func-
tions, uncontrolled hypertension, bronchial asthma, dysrhyth-
mias, heart failure, Glasgow coma scale <12, the need for
postoperative ventilation, history of allergy to the study drugs
and surgeries lasting more than 6 hr.
2.2. Induction and maintenance of anesthesia
Before induction of anesthesia, all patients were cannulated
with an 18 gauge venous cannula and premedicated with IV
ranitidine (50 mg), metoclopropramide (10 mg) and dexam-
ethasone (0.15 mg/kg), and standard monitors were applied
in the form of ECG lead II (with ST segment analysis), pulse
oximetry and non-invasive blood pressure. Invasive blood
pressure was inserted preoperatively under local anesthesia,
peripheral nerve stimulator (PNS) was used to monitor muscu-
lar relaxation and a capnogram was applied after induction of
anesthesia as well as a central venous line.
Anesthesia was induced using propofol (2 mg/kg) and fen-
tanyl (2 lg/kg), intubation was facilitated by the use of atra-
curium (0.5 mg/kg) and done after disappearance of second
twitch of train of 4 using PNS, and lidocaine (1.5 mg/kg)
was given 90 s before intubation.
Anesthesia was maintained with isoflurane (1–1.5% end
tidal) in O2. Further fentanyl was given as 1 lg/kg at the time
of skin incision and again at the time of bur hole.
Mechanical ventilation was adjusted to maintain an end
tidal CO2 between 30 and 35 mmHg. Muscle relaxation was
maintained by an infusion of atracurium (0.5 mg/kg/hr).
All patients received intraoperative fluid in the form of nor-
mal saline infusion (3 ml/kg/hr) and voluven (500 ml), and cen-
tral venous pressure was maintained between 5 and 8 cm H2O.
Mannitol (0.5 gm/kg) was administered shortly after induction
as a brain dehydrating measure. Plasma expander was admin-
istered to maintain normovolemia and blood transfusion
started if the patient hemoglobin level decreased to 68 gm%.
2.3. Recovery
By the end of surgical homeostasis and start of dural closure,
patients were divided randomly into 3 equal groups.
Infusions were prepared by a clinical pharmacist not
included in data collection. Group ‘‘dex” received dexmedeto-
midine intravenous infusion in a rate of 1 lg/kg/hr prepared as
100 l dexmedetomidine in 50 ml saline. Group ‘‘labetalol”
received labetalol infusion in a rate of 0.5 mg/kg/hr prepared
as 50 mg labetalol in 50 ml saline. Group ‘‘control” received
normal saline infusion. The rate of the infusion in all groups
was 0.5 ml/kg/hr. The attending anesthetist was blinded to
the type of solution injected. Atracurium infusion was
discontinued after closure of the dura, while isoflurane was
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was done using nitroglycerine starting at 1 lg/kg/min if the
change in systolic blood pressure exceeded 25% of its prein-
duction value. When hypotension (decrease in SBPP 25%
from preinduction value) occurred, ephedrine 3 mg increments
were given whereas atropine (0.5 mg IV bolus) was given for
patients experiencing bradycardia (HR <45 beat/min).
Residual effects of muscle relaxant were reversed with
neostigmine (0.05 mg/kg) and atropine 0.01 mg/kg upon
appearance of second twitch of train of four. Patients were
extubated upon localization to pain. The study infusions were
stopped at the time of extubation.
The patients were then transferred to the PACU where all
haemodynamic parameters (Heart rate, blood pressure and
O2 saturation) were monitored and patients received O2 sup-
plementation until discharge to the ward 4 hr later.
2.4. Data collected
Systolic (SBP), diastolic (DBP), mean arterial blood pressure
(MAP) and heart rate (HR) were recorded at the following
times: Before induction of anesthesia, before dural closure,
5 min after drug administration, every 5 min intraoperative till
extubation, at the time of extubation, every 15 min for 4 hr in
the PACU.
Number of patients needing nitroglycerin infusion as well
as the total amount consumed by each patient was recorded,
and number of patients requiring atropine and/or ephedrine
was recorded as well as the total amount of ephedrine given.
Extubation time (defined as the time between the discontin-
uation of inhalation agents and extubation) was also
measured.
2.5. Sample size
Total sample size of 75 patients randomly allocated into three
equal groups. Estimation of sample size was performed using
computer program G*Power 3 for Windows (Franz Faul,
Universita¨t Kiel, Germany) with 80% power to detect a clini-
cally significant difference of 10% or more in the SBP (effect
size f= 0.424, a error = 0.05, b error = 0.2) with a result of
66 patients. We included 75 patients to guard against losses
in the perioperative period.
2.6. Statistical analysis
Data were coded and entered using the statistical package
SPSS version 22. Values were expressed as mean and SD forTable 1 Demographic data and duration of surgery.
Dex group (n= 25) Labetalol
Age (y) 42 ± 12 44 ± 6
Weight (kg) 74 ± 16 80 ± 10
Height (cm) 168 ± 11 170 ± 8
Gender (female nMale) 17n8 68%n32% 11n14
(ASA I/II) 19n6 76%n24% 15n10
Duration of surgery (min) 256 ± 66 247 ± 74
Data are expressed as Mean ± SD or total number and (%).quantitative variables and frequencies (number of cases) and
relative frequencies (percentages) for categorical variables.
Comparisons between different groups were carried out by
one way analysis of variance (ANOVA) with post hoc test.
For comparing categorical data, Chi square (v2) test was
performed. Fisher’s Exact test was used instead when the
expected frequency is less than 5. P-values less than 0.05 were
considered as statistically significant while P-values < 0.001
were mentioned and considered highly statistically significant.
3. Results
3.1. Demographic data and duration of surgery
There were no significant differences in demographic data
between the three groups as regards patients’ age, sex, height,
body weight, ASA physical status and duration of surgery
(Table 1).
3.2. Operative data
There was no statistically significant difference between the
three groups as regards tumor site (Table 2).
3.3. Comparison between the three groups as regards
nitroglycerin and ephedrine administration
As regards ephedrine administration, there was no statistically
significant difference between the three groups.
However, there was a highly statistically significant differ-
ence in the amount of nitroglycerin received between the three
groups.
As regards the number of patients receiving nitroglycerin
there was a statistically significant difference between the three
groups. 22 patients (88%) in the control group received nitro-
glycerin; meanwhile, only 5 patients in labetalol group (20%)
and 8 patients (32%) in dexmedetomidine group received
Nitroglycerin (Table 3).
3.4. Comparison between the three groups as regards
hemodynamics
3.4.1. A - Heart rate
As regards the heart rate (HR), there was no statistically signif-
icant difference between the three groups in baseline readings
before induction of anesthesia as well as before dural closure.
After drug administration, a statistically significant differ-
ence was observed between the three groups (p value < 0.05)group (n= 25) Control group (n= 25) P value
40 ± 11 0.339
79 ± 11 0.246
164 ± 6 0.066
44%n56% 12n13 48%n52% 0.190
60%n40% 16n9 64%n36% 0.458
243 ± 69 0.69
Table 2 Comparison among the three groups as regards site of the lesion.
Dex group (n= 25) Labetalol group (n= 25) Control group (n= 25) P value
Site of lesion Convexity meningioma 7 28% 12 48% 10 40% 0.749
Frontal meningioma 10 40.0% 8 32% 8 32%
Parietal glioma 4 16% 3 12% 2 8%
Temporal glioma 4 16% 2 8.0% 5 20%
Data are expressed as total number and (%).
Table 3 Comparison between the three groups as regards nitroglycerin and ephedrine administration.
Dex group (n= 25) Labetalol group (n= 25) Control group (n= 25) P value
Total nitroglycerin dosage (mg) 0.13 ± 0.22 0.04 ± 0.08 8.08 ± 11.28 <0.001*
Total ephedrine dosage (mg) 1.44 ± 3.98 1.80 ± 3.69 0.00 ± 0.00 0.115
Number of patients received nitroglycerin 8 (32%) 5 (20%) 22 (88%) 0.032*
Number of patients received ephedrine 3 (12%) 4 (16%) 0 (0%) 0.150
Data are expressed as Mean ± SD or total number and (%).
* Denotes statistically significant difference between the 3 groups (p-value < 0.05).
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time of extubation where HR was less in both labetalol and
dexmedetomidine groups than in the control group.
The observed statistically significant difference was high at
several time intervals: HR at 30 min (dex group 88.55 ± 8.12,
labetalol group 82.60 ± 11.31, control group 103.68 ± 24.31,
p value < 0.001); at 35 min (dex group 86.61 ± 7.04, labetalol
group 70.27 ± 15.98, control group 97.70 ± 18.71, p value <
0.001), at 40 min (dex group 86.72 ± 7.58, labetalol group
73.60 ± 9.42, control group 89.47 ± 5.94, p value < 0.001),
and at the time of extubation (dex group 99.84 ± 16.48,
labetalol group 88.36 ± 18.94, control 112.76 ± 18.68,
p value < 0.001).
As regards the heart rate between dexmedetomidine and
labetalol groups after drug administration, it was lower in
labetalol group. The difference was statistically significant
(P value < 0.05) at 35 and 40 min.
In the PACU, a statistically significant difference was
observed between the three groups in most of the readings
(p value < 0.05) where HR was lower in the labetalol group
than both the dexmedetomidine and the control groups
(Fig. 1).
The observed statistical significance was high at several
time intervals: at 30 min (dex group 97.84 ± 8.94, labetalol
group 82.76 ± 3.49, control group 93.88 ± 16.17, p value <
0.001), at 1:00 hr (dex group 96.44 ± 4.26, labetalol group
85.84 ± 5.37, control group 91.44 ± 13.91, P value < 0.001)
at 1:30 hr (dex 94.20 ± 4.60, labetalol 80.48 ± 9.51, control
94.88 ± 17.91, p value < 0.001) (Fig. 1). As regards the heart
rate between dexmedetomidine and labetalol groups after dis-
continuing the drugs, it was lower in labetalol group. The dif-
ference was statistically significant (P value < 0.05) at 45 min,
and at 1:45, 2:00, 4:00 hr. It was highly statistically significant
(P value < 0.001) at 15, 30 min, and at 1:00, 1:30 hr (Fig. 1).
3.4.2. B - Systolic blood pressure
As regards SBP, there was no statistically significant difference
between the three groups in baseline readings before induction
of anesthesia as well as before dural closure.
After drug administration, a statistically significant differ-
ence was observed between the three groups (p value < 0.05)at the following times 5, 10, 20, 25, 30 and 35 min. SBP was
lower in dexmedetomidine group than in both the labetalol
and the control groups.
The observed statistical significance was high at several
time intervals: at 5 min (dex group 122.16 ± 15.71, labetalol
group 125.16 ± 13.92, control group 138.12 ± 13.09,
P value < 0.001), at 25 min (dex group 108.48 ± 13.08,
labetalol group 130.8 ± 10.92, control group 129.48 ± 23.24,
P value < 0.001), at 35 min (dex group 110.78 ± 14.31,
labetalol group 131.6 ± 13.47, control group 129.7 ± 8.34,
P value < 0.001).
In the PACU, a statistically significant difference was
observed between the three groups at several time intervals
at 30 min and at 1, 1.15, 1.30, 1.45, 2.30, 3:00, 3.15, 3.30 hr
(p value < 0.05). The SBP was lower in both dexmedetomidine
and labetalol groups than in the control group.
The observed statistical significance was high at 30 min
(dex 114.04 ± 13.84, labetalol 121.12 ± 11.3, control
127.68 ± 7.39, p value < 0.001); at 1:30 hr (dex 123.72 ±
13.2, labetalol 119.56 ± 5.66, control 129.3 6 ± 11.88, p value
0.008) and at 3:30 hr (dex 116.2 ± 15.95, labetalol
124.36 ± 12.73, control 132.48 ± 7.27, p value < 0.001).
As regards the SBP between dexmedetomidine and
labetalol groups after discontinuing the drugs, there was no
statistically significant difference (Fig. 2).
3.4.3. C - Diastolic blood pressure
As regards DBP, there was no statistically significant
difference between the three groups in baseline readings
before induction of anesthesia as well as before dural
closure.
Statistically significant differences were observed between
the three groups (p value < 0.05) in the readings, 20, 25, 30,
35 min after drug administration. DBP was lower in the
dexmedetomidine group than in both the labetalol and the
control groups.
The statistically significant difference was high at 20 min
(dex group 59.4 ± 5.69, labetalol group 69.4 ± 11.29, control
group 73.08 ± 8.15, p value < 0.001) and at 25 min
(dex group 60.04 ± 7.14, labetalol group 72.56 ± 8.29, con-
trol 76.72 ± 16, p value < 0.001).
* denotes statistically significant difference between the 3 groups ( p-value < 0.05) 
# denotes statistically significant difference between dex and labetalol groups ( p-value < 0.05) 
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Figure 1 Comparison between the three groups as regards HR.
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between the three groups at 30 min, 1:45, 2:45, 3:00, 3:30, and
4 hr readings.
The difference was highly statistically significant at 3 hr
(dex group 69.04 ± 9.89, labetalol group 68.88 ± 5.54,
control group 77.4 ± 4.25, p value < 0.001).
As regards the DBP between dexmedetomidine and labeta-
lol groups after discontinuing the drugs, there was no statisti-
cally significant difference except at 1:45 and 4:00 hr (Fig. 3).
3.4.4. C - Mean blood pressure
As regards MAP, there was no statistically significant differ-
ence between the three groups in baseline readings before
induction of anesthesia as well as before dural closure.
Statistically significant differences between the three groups
(p value < 0.05) were observed at 5, 10, 20, 25, 30 and 35 min
after drug administration, as well as at the time of extubation.
MAP was lower in dexmedetomidine group than in both the
labetalol and the control groups.
The observed statistically significant difference was high at
5 min (dex group 87.32 ± 4.02, labetalol group 94 ± 7.72,
control 96.64 ± 8.48, p value < 0.001), at 20 min (dex group
77.12 ± 5.64, labetalol group 87.36 ± 14.31, control
group 89.84 ± 5.2, p value < 0.001), and at 25 min (dex group
79.74 ± 7.58, labetalol group 83.8 ± 12.88, control group
99.12 ± 19.14, p value < 0.001).
Regarding MAP between dexmedetomidine and labetalol
groups after drug administration, it was lower in dexmedeto-
midine group in most of the readings. The difference was sta-
tistically significant (P value < 0.05) at 5, 20, 30 and 35 min.In the PACU, there were statistically significant differences
between the three groups at 1:00, 1:15, 1:45, 2:15, 2:45, 3:00,
3:15, 3:30, 3:45 and 4 hr readings.
Regarding the MAP between the dexmedetomidine
and labetalol groups in the PACU after discontinuing the
drugs, statistically significant differences (P value < 0.05)
were only observed at 1:45 and 3:30 and 4:00 hr, where
MAP was lower in dexmedetomidine group except at 4:00 hr
(Fig. 4).
3.5. Comparison between the three groups as regards time to
extubation
There was no statistically significant difference between the
three groups as regards time to extubation (Table 4).4. Discussion
The present study showed that both dexmedetomidine in a
dose of 1 lg/kg/hr and labetalol 0.5 mg/kg/hr starting at dural
closure had a significant effect in reducing HR, SBP, DBP,
MAP during emergence from anesthesia. The number of
patients needing nitroglycerin was significantly lower in
dexmedetomidine group and labetalol group in comparison
with the control group. This was without prolonging the time
to emergence in both dexmedetomidine and labetalol groups in
comparison with control group. Moreover the HR was signif-
icantly lower in labetalol group in comparison with the
dexmedetomidine group, whereas SBP, DBP and MAP were
* denotes statistically significant difference between the 3 groups ( p-value < 0.05) 
# denotes statistically significant difference between dex and labetalol groups (  p-value < 0.05) 
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Figure 2 Comparison between the three groups as regards SBP.
468 T.A.M. Radwan et al.lower in dexmedetomidine group during emergence from
anesthesia.
To our knowledge no comparative study between the
hemodynamic effects of labetalol and dexmedetomidine on
emergence from anesthesia after cranial surgeries is yet
available.
The findings of the present study could be explained as
follows: labetalol is a combined selective alpha-1 and non-
selective beta-adrenergic receptor blocker with an alpha to
beta blocking ratio of 7:1 [7], with the onset of hypotensive
response beginning within two to 5 min after IV administra-
tion, reaching a peak at 5–15 min, lasting for about two to
4 hr and with an elimination half life of 5.5 hr, though this
variability makes labetalol very difficult to titrate as a contin-
uous infusion [7]. However, it preserves cerebral blood flow
and autoregulation, and does not affect global or regional
cerebral blood flow or cerebral metabolic oxygen consumption
[16].
Dexmedetomidine is a highly selective a2-agonist with an
affinity ratio a2:a1 of 1620:1. It causes a dose dependent
decrease in arterial blood pressure and HR possibly due to a
decrease in serum norepinephrine concentrations. The effect
of a2 agonists on hemodynamics is caused by stimulation of
a2 adrenoceptors in the central nervous system [17,18]. It has
a very short half-life of distribution, approximately 6 min,
and elimination time of 2 hr [19].
Furthermore, The neuroprotective effect of dexmedeto-
midine is thought to be due to the reduction of the levels of
circulating and brain catecholamines and consequently,
balancing the ratio between cerebral oxygen demand to supply,reducing excitotoxicity, and improving the perfusion in the
ischemic penumbra. It reduces the levels of the glutamate
responsible for cellular brain injury, especially in subarachnoid
hemorrhage. It has been shown to limit the morphologic and
functional effects after ischemic (focal and global) and
traumatic injury to the nervous system [12,20].
The results of the present study were in agreement with
those of the study done by Guler et al. in 2005, they studied
the effect of single dose dexmedetomidine on airway and circu-
latory reflexes during emergence from anesthesia in sixty
patients undergoing intraocular surgeries who received a stan-
dard anesthetic. Five minutes before the end of surgery, they
were randomly allocated to receive either dexmedetomidine
0.5 lg/kg (n 30) or saline placebo (n 30) intravenously over
60 s. Guler et al. found that there was less significant increase
in HR, SBP and DBP at extubation with dexmedetomidine
with no difference in the time for tracheal extubation or for
emergence from anesthesia [21]. It should be noted that in
our study the use of dexmedetomidine was in the form of
infusion at a dose of 1 lg/kg/hr that starting at dural closure
and continuing to the time of extubation.
Moreover, Bindu et al. in 2013 studied the effect of an
intravenous infusion of dexmedetomidine against placebo,
over 15 min before anticipated time of end of surgery. Fifty
patients scheduled for elective general surgical, urological
and gynecological were randomly allocated to receive either
dexmedetomidine or saline, and HR, SBP, DBP and MAP
were recorded at the start of injection, at 1, 3, 5, 10, 15 min till
extubation, at 1, 3, 5 min after extubation, and thereafter every
5 min for 30 min. They observed a significantly higher HR,
* denotes statistically significant difference between the 3 groups ( p-value < 0.05) 
# denotes statistically significant difference between dex and labetalol groups ( p-value < 0.05) 
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Figure 3 Comparison between the three groups as regards DBP.
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with our study taking into consideration the difference in sur-
gical group, dosing and the time of start of infusion [22].
Furthermore, Kothari et al. in 2014, compared the effect of
dexmedetomidine versus lignocaine in attenuation of circula-
tory and airway responses during endotracheal extubation in
craniotomies. The drugs were given 5 min before the extuba-
tion over a period of 60 s, dexmedetomidine in a dose of
0.5 lg/kg and lignocaine in a dose of 1.5 mg/kg. Kothari
et al. found that Single dose of dexmedetomidine given 5 min
before extubation produced significant attenuation of circula-
tory and airway responses as compared to Lignocaine in cran-
iotomies which comes in agreement with our study though
there is a difference in the dose used, the time and the way
of administration [23].
In addition, Bekker et al. in 2008 designed a study in which
Patients scheduled for elective craniotomy were randomly
assigned to receive either sevoflurane–opioid or sevoflurane–
opioid–dexmedetomidine anesthesia. Opioids, sevoflurane,
and vasoactive medications were titrated in a routine manner,
by using indices, which assess a global hemodynamic stability
of the anesthetics concluded that intraoperative dexmedeto-
midine infusion was effective for blunting the increases in
SBP perioperatively, which is consistent with our study; how-
ever, there is a difference in the design between our study and
Bekker’s study, in our study dexmedetomidine was given as
infusion only started at the time of dural closure, while inBekker’s study, dexmedetomidine started as loading and main-
tenance from start of the operation [24].
Also Ilhan et al. in 2010, studied in a double-blind prospec-
tive clinical study, the effects of fentanyl and dexmedetomidine
as adjuvant agents in supratentorial craniotomies on the
hemodynamic changes during perioperative and recovery peri-
ods, recovery times and side effects. Thirty patients undergoing
intracranial tumor surgeries were divided into two groups. In
one group (n= 15), dexmedetomidine was infused as a
1 lg/kg bolus dose 10 min before induction of anesthesia and
maintained with 0.4–0.5 lg/kg/min during the operation, and
fentanyl was given as a 2 lg/kg at induction. In the other
group (n= 15), patients were given fentanyl 4 lg/kg before
induction and 0.02 lg/kg/min as an infusion for maintenance
of anesthesia. Ilhan et al. concluded that dexmedetomidine
controlled the hemodynamic changes better than fentanyl peri-
operatively, after extubation and during the early postopera-
tive period, which supports the results of our study [25].
Moreover, in a comparative study by Gosai et al. in 2015,
seventy-five patients undergoing cranial surgeries were ran-
domly divided into 3 groups to receive either 0.5 lg/kg
dexmedetomidine or 1.5 mg/kg lignocaine or normal saline
as intravenous boluses over one minute after return of sponta-
neous ventilation. They found that a single dose of intravenous
dexmedetomidine administered before tracheal extubation
resulted in an effective attenuation of hemodynamic responses
to extubation in comparison with lignocaine [26]. Those results
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Figure 4 Comparison between the three groups as regards MAP.
Table 4 Comparison between the three groups as regards the time to extubation.
Dex group (n= 25) Labetalol group (n= 25) Control group (n= 25) P value
Time to extubation (min) 15.28 ± 4.99 12.64 ± 4.05 15 ± 4.55 0.085
Data are expressed as Mean ± SD.
470 T.A.M. Radwan et al.come in accordance with the results of the present study taking
into consideration the difference in the dose and the way of
administration.
In a recent study, Mistry et al. in 2016 compared the effect
of both dexmedetomidine and verapamil on attenuation of
extubation responses in thirty patients undergoing spinal surg-
eries under general anesthesia. At the end of surgery just
before extubation, group V received 0.1 mg/kg verapamil
and group D received 0.3 lg/kg as intravenous bolus over
one minute, and hemodynamic parameters including HR,
SBP, DBP and MAP were recorded just before administration
of the medications, 2 min afterward, after oral suction, imme-
diately after extubation, and 1, 3, 5 and 10 min post extuba-
tion. Other parameters were duration of emergence and
extubation, quality of extubation, Richmond Agitation Seda-
tion Scale score and time to reach modified Aldrete score
P9. They concluded that a single dose of dexmedetomidine
administered just before extubation resulted in significant
attenuation of circulatory and airway responses in comparison
with a single dose of verapamil [27]. This comes in agreement
with the present study though the study groups, the timing, the
dosage and the way of administration were different.Regarding the hemodynamic effects of labetalol, a study by
Kross et al. compared the efficacy of the combination of
enalaprilat/labetalol with that of enalaprilat/nicardipine to pre-
vent emergence postcraniotomy hypertension. Forty-two
patients received enalaprilat 1.25 mg IV at dural closure fol-
lowed by either multidose nicardipine 2 mg IV or labetalol
5 mg IV to maintain the SBP below 140 mmHg. SBP was sim-
ilarly controlled in both groups. There was a marginally smaller
incidence of failures and adverse effects with labetalol. Blood
pressure profiles were similar for both groups [28]. That study
is in agreement with the present study except that labetalol in
the present study was given as a sole antihypertensive agent
starting at dural closure as an infusion in a rate of 0.5 mg/kg/hr.
Congruent with our study, Muzzi et al. compared the
effects of esmolol and labetalol in treating increases in blood
pressure during emergence and recovery from anesthesia after
intracranial surgery. Both esmolol and labetalol were equally
effective in controlling systolic blood pressure on emergence
and in the recovery room in patients undergoing intracranial
surgery. However, decreases in heart rate were significantly
more frequent in the immediate postoperative period in
patients given labetalol [2].
Dexmedetomidine versus labetalol infusions for controlling emergence hypertension 471Furthermore, Sladen et al. in a multicenter study evaluated
the efficacy and safety of intravenous (IV) labetalol for the con-
trol of elevated blood pressure in the intensive care unit (ICU)
in 65 patients within 4 hr following coronary artery bypass
grafting (CABG). Intravenous labetalol was loaded incremen-
tally (5, 10, 20, and 40 mg at 10-min intervals) to a maximum
cumulative dose of 75 mg, until either SBP decreased 10% or
DBP decreased 10% and was less than 90 mmHg. Responders
were entered into a 6-hr maintenance period, and received 5–
40 mg of IV labetalol every 10 min as needed for blood pressure
control. Hemodynamic data were recorded at baseline, just
before each dose of labetalol during the loading period, and
at the end of the maintenance period. Alternative therapy
was given in the case of no response or adverse events. Intra-
venous labetalol successfully controlled post-CABG hyperten-
sion in 55 of 65 patients (85%); of these, 46 responded to 35 mg
or less. Sladen concluded that IV labetalol appears to be a safe,
effective agent in controlling post-CABG hypertension, with
the added potential benefit of enhanced myocardial oxygen bal-
ance [29]. However, Sladen et al., study differs from our study
in various aspects, regarding the patient group, the method and
the timing of labetalol administration; however, both studies
share the same conclusion of labetalol safety and efficacy in
managing postoperative hypertension.
5. Pitfalls
The lack of assessment of postoperative sedation score and the
lack of assessment of the effect of the drugs on airway reflexes
such as gag and cough reflexes are drawbacks of this study.
Furthermore, other studies are needed to compare the
responses of the different age groups as well as controlled
hypertensive patients to the study drugs, the effects of different
dosages of dexmedetomidine, the infusion versus bolus doses,
the different timings of the initiation of the drugs and whether
dexmedetomidine can also be used for hypotensive anesthesia
in surgical procedures other than neurosurgical operations.
6. Conclusion
From the present study we can conclude that dexmedeto-
midine infusion in a dose of 1 lg/kg/hr and labetalol infusion
in a dose of 0.5 mg/kg/hr which started at dural closure had a
significant effect in reducing the incidence and the extent of
emergence hypertension without prolonging the time needed
for extubation. There was more reduction of the SBP, MAP
and DBP in the dexmedetomidine group and of the HR in
the labetalol group in comparison with the other two groups.
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